Endra Life Sciences INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
ENDRA Life Sciences Inc. has filed a definitive proxy statement with the SEC, outlining information required for an upcoming shareholder meeting.
NASDAQ
ENDRA Life Sciences Inc. calls for its 2025 Annual Meeting to vote on proposals including a significant increase in authorized shares and officer liability limitations.
NASDAQ
ENDRA Life Sciences Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
DEF 14A: ENDRA Life Sciences Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance
ENDRA Life Sciences is asking stockholders to approve a reverse stock split proposal, with ratios ranging from 1-for-4 to 1-for-35, to increase its stock price and maintain its Nasdaq listing.
NASDAQ
ENDRA Life Sciences is appealing a Nasdaq delisting determination after its stock price fell below $0.10, and is seeking a reverse stock split at its upcoming annual meeting to regain compliance.
NASDAQ
ENDRA Life Sciences Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
ENDRA Life Sciences is holding its annual stockholder meeting on August 6, 2024, to vote on key proposals including director elections, executive compensation, warrant share issuance, increasing authorized shares, a potential reverse stock split, and auditor ratification.